Loading...
Loading...
PRVB| Name | Value |
|---|---|
| Revenues | 10.8M |
| Cost of Revenue | 0.5M |
| Gross Profit | 10.3M |
| Operating Expense | 50.5M |
| Operating I/L | -40.2M |
| Other Income/Expense | 0.6M |
| Interest Income | 1.3M |
| Pretax | -39.6M |
| Income Tax Expense | -6.3M |
| Net Income/Loss | -33.3M |
Provention Bio, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of therapeutics to intercept and prevent immune-mediated diseases. The company's product candidates include PRV-031 teplizumab and monoclonal antibodies in Phase III clinical trial for type one diabetes interception, PRV-3279 for lupus treatment, PRV-101 coxsackie virus B vaccine for preventing acute CVB infections and onset of T1D, and PRV-015 for gluten-free diet non-responding celiac disease. Provention Bio, Inc. also has license and collaboration agreements with Amgen Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. for the development and commercialization of certain products.
